Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 13/20 | 0.38 |
| ▸ | CA2 | P00918 | 13/20 | 0.38 |
| ▸ | CA9 | Q16790 | 13/20 | 0.38 |
| ▸ | CA1 | P00915 | 12/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 11/20 | 0.38 |
| ▸ | CA3 | P07451 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CA6 | P23280 | 2/20 | 0.38 |
| ▸ | CA5A | P35218 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5031362 | 0.76 | FGFR1 (0.46) | FGFR1CA12CA2CA9CA1 | |
| SCHEMBL5032715 | 0.75 | FGFR1 (0.43) | FGFR1CA12CA2CA9CA1 | |
| SCHEMBL6668410 | 0.72 | FGFR1 (0.43) | FGFR1CA12CA2CA9CA1 | |
| SCHEMBL5485625 | 0.69 | FGFR1 (0.46) | FGFR1JAK2JAK3LTA4H | |
| SCHEMBL4059255 | 0.69 | FGFR1 (0.53) | FGFR1MKNK1MKNK2JAK2JAK3 | |
| SCHEMBL3817799 | 0.66 | CA12 (0.38) | CA12CA2CA9CA1CA14 | |
| SCHEMBL5030414 | 0.66 | FGFR1 (0.46) | FGFR1MKNK1MKNK2LTA4H | |
| SCHEMBL25291568 | 0.65 | FGFR1 (0.53) | FGFR1MKNK1MKNK2JAK2JAK3 | |
| SCHEMBL18330920 | 0.65 | FGFR1 (0.53) | FGFR1MKNK1MKNK2JAK2JAK3 | |
| SCHEMBL256337 | 0.65 | FGFR1 (0.53) | FGFR1MKNK1MKNK2JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098221-B2 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-08-29 | — | — | US | disclosed |
| US-20050282854-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-12-22 | — | — | US | disclosed |
| US-6969722-B2 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-11-29 | — | — | US | disclosed |
| US-6903113-B2 | Urea substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-07 | — | — | US | disclosed |
| US-6878719-B2 | Sulfonamido substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040186128-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-23 | — | — | US | disclosed |
| EP-1453829-A1 | SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES | 3M Innovative Properties Company (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040157879-A1 | Urea substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-08-12 | — | — | US | disclosed |
| US-20040147533-A1 | Sulfonamido substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-29 | — | — | US | disclosed |
| US-6720333-B2 | IMMUNE RESPONSE MODIFIERS; CYTOKINE BIOSYNTHESIS; VIRAL AND NEOPLASTIC DISEASES; N-(4-(4-AMINO-6,7-DIMETHYL-1H-IMIDAZO (4,5-C)PYRIDIN-1-YL)BUTYL)BENZAMIDE | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-13 | — | — | US | disclosed |
| US-6696465-B2 | INDUCING BIOSYNTHESIS OF CYTOKINES; VIRAL AND NEOPLASTIC DISEASES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-02-24 | — | — | US | disclosed |
| US-20030195209-A1 | Urea substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-16 | — | — | US | disclosed |
| US-20030186949-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-02 | — | — | US | disclosed |
| US-20030176458-A1 | Urea substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-09-18 | — | — | US | disclosed |
| US-20030162806-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-08-28 | — | — | US | disclosed |
| WO-2003050117-A1 | SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| US-6545016-B1 | Inducing cytokine biosynthesis; treating a viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-08 | — | — | US | disclosed |
| US-6545017-B1 | Inducing cytokine biosynthesis; treating a viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-08 | — | — | US | disclosed |
| US-6525064-B1 | Immune response modifiers; can induce the biosynthesis of various cytokines; | 3M INNOVATIVE PROPERTIES COMPANY | 2003-02-25 | — | — | US | disclosed |
| US-20020107262-A1 | SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2002-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186128-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | FGFR1 771/4885CA12 4123/4885CA2 3331/4885 |
| US-20030176458-A1 | Urea substituted imidazopyridines | EIF2AK2, UMPS, IRF3 | FGFR1 2758/4885CA12 4675/4885CA2 4192/4885 |
| US-20030195209-A1 | Urea substituted imidazopyridines | EIF2AK2, UMPS, IRF3 | FGFR1 2758/4885CA12 4675/4885CA2 4192/4885 |
| US-20050282854-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | FGFR1 771/4885CA12 4123/4885CA2 3331/4885 |
| US-20040157879-A1 | Urea substituted imidazopyridines | EIF2AK2, UMPS, IRF3 | FGFR1 2758/4885CA12 4675/4885CA2 4192/4885 |
| US-20020107262-A1 | SUBSTITUTED IMIDAZOPYRIDINES | IRF3, IFNG, EIF2AK2 | FGFR1 863/4885CA12 4596/4885CA2 3956/4885 |
| US-20040147533-A1 | Sulfonamido substituted imidazopyridines | IRF3, EIF2AK2, MYD88 | FGFR1 436/4885CA12 3309/4885CA2 2548/4885 |
| US-20030162806-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | FGFR1 771/4885CA12 4123/4885CA2 3331/4885 |
| US-20030186949-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | FGFR1 771/4885CA12 4123/4885CA2 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.